Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Chi-Med's Innovative Drug Portfolio: Eight Candidates in 31 Trials

publication date: Aug 2, 2017
While announcing 2017 first-half financial results, Hutchison China MediTech (Chi-Med) provided a broad overview of its wide-ranging innovative drug portfolio. Comprised of eight drug small-molecule candidates, the portfolio is currently involved in 31 clinical trials. There are many signs of progress: earlier this year, Chi-Med filed its first NDA, a request for China approval of fruquintinib, a VEGFR inhibitor, as a treatment for colorectal cancer. Chi-Med also started its first global Phase III registration trial (for savolitinib), and it has five other pivotal Phase III studies underway with three more close to starting. More details....

Stock Symbol: (AIM/NSDQ: HCM)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
November 8-11, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022